INFLIXIMAB , TOCILIZUMAB , Cosentyx 300 mg solution for injection in pre-filled pen, ADALIMUMAB clinical trials

STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients

This study, called STARS, is looking at a new medicine for Takayasu arteritis, a condition that makes blood vessels inflamed. Researchers want to see if this medicine, called secukinumab (Cosentyx), works better and is safer than usual treatments for severe forms of the disease.